STOCK TITAN

BeiGene, Ltd. - $BGNE STOCK NEWS

Welcome to our dedicated page for BeiGene, Ltd. news (Ticker: $BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene, Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene, Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene, Ltd.'s position in the market.

Rhea-AI Summary

BeiGene announced new analyses for BRUKINSA® (zanubrutinib) at the ASCO Annual Meeting 2024. The data underline BRUKINSA's efficacy and safety in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) compared to other BTK inhibitors (BTKis).

A network meta-analysis highlighted BRUKINSA's superior progression-free survival (PFS) over acalabrutinib in high-risk relapsed/refractory CLL patients. Additional findings indicated a trend towards better overall survival (OS) and overall response (ORR) rates.

A retrospective analysis from Kaiser Permanente revealed that BRUKINSA is well-tolerated, with lower treatment-limiting adverse events, particularly cardiac-related, compared to ibrutinib. A post-hoc analysis of the ALPINE trial showed patients on BRUKINSA had less frequent initiation of new antihypertensive medications.

Overall, BRUKINSA demonstrates a favorable clinical profile, offering significant insights for oncologists in treatment decision-making for CLL and SLL patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
Rhea-AI Summary

BeiGene announced it will present new data from its hematology portfolio at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024.

Highlights include 28 abstracts, with four oral presentations. Key studies focus on BRUKINSA® (zanubrutinib), sonrotoclax, and BGB-16673. BRUKINSA, in combination with venetoclax, showed strong efficacy and favorable safety in high-risk CLL/SLL patients.

Sonrotoclax demonstrated promising safety and efficacy as a monotherapy and in combination therapies, particularly with BRUKINSA. Also, BGB-16673, a BTK degrader, showed encouraging results in BTK inhibitor-resistant diseases.

These findings underscore BeiGene's commitment to advancing treatment options for B-cell malignancies and other hematological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

BeiGene reported total revenues of $752 million in the first quarter of 2024, with product revenue reaching $747 million, an 82% increase from the prior-year period. BRUKINSA revenue was $489 million, showcasing growth in the U.S. and Europe. The company is focusing on advancing its late-stage hematology pipeline, improving operating leverage, and aiming for sustainable profitability. Key updates include the FDA approval for BRUKINSA in follicular lymphoma and the sales growth of TEVIMBRA in various indications. The company also highlighted progress in its hematology and solid tumor programs, along with key pipeline advancements in lung, breast, and gastrointestinal cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
Rhea-AI Summary

BeiGene, a global oncology company, released its 2023 Responsible Business & Sustainability Report, highlighting achievements, expansion plans, and commitment to innovation. Key points include treating over 1 million patients with BTK inhibitor BRUKINSA and anti-PD-1 antibody TEVIMBRA, opening a new facility in the U.S., and setting quantitative climate goals. The report focuses on advancing global health, empowering colleagues, innovating sustainably, and operating responsibly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
Rhea-AI Summary
BeiGene, a global oncology innovator, is set to present new data at the 2024 ASCO Annual Meeting showcasing the efficacy and safety of BRUKINSA and TEVIMBRA across various B-cell malignancies and solid tumors. The company will highlight BRUKINSA's differentiated clinical profile and present data comparing its efficacy with other treatments in chronic lymphocytic leukemia. TEVIMBRA will be featured in multiple presentations, demonstrating its potential across different tumor types. The company's solid tumor development program will be a focal point at the meeting, with new data from the RATIONALE-306 study on TEVIMBRA's efficacy in esophageal squamous cell carcinoma. BeiGene's commitment to addressing unmet patient needs through innovative treatments is evident in the research outcomes they will share at ASCO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
Rhea-AI Summary
BeiGene receives European Commission approval for tislelizumab as a treatment for non-small cell lung cancer, marking the second approval in the region. The comprehensive development program included three Phase 3 clinical trials demonstrating the benefits of tislelizumab for both treatment-naïve and relapsed NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
none
Rhea-AI Summary
BeiGene's TEVIMBRA receives FDA approval for treating adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy, showing significant survival benefits in Phase 3 RATIONALE 302 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Pi Health, a subsidiary of BeiGene, Ltd. (NASDAQ: BGNE), secures over $30M in Series A funding to revolutionize global access to clinical trials and innovative medicines. The funding round, led by AlleyCorp and Obvious Ventures, aims to address the inefficiencies in the clinical trial process by leveraging cutting-edge technology. Pi Health's FICS software streamlines data collection and accelerates drug development, potentially saving lives and reducing costs. The company's mission is to democratize cancer care and research by increasing patient enrollment and enhancing global access to life-saving treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
-
Rhea-AI Summary
Armenia and Nepal are the first countries to receive BRUKINSA, a treatment for chronic lymphocytic leukemia, as part of a collaboration between Max Foundation, BeiGene, and BeiGene Foundation. The initiative aims to provide access to the medicine in 29 low- and middle-income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
none
Rhea-AI Summary
BeiGene's BRUKINSA receives accelerated approval from the FDA for the treatment of relapsed or refractory follicular lymphoma in combination with obinutuzumab, marking its fifth indication in B-cell malignancies. The approval is based on positive results from the ROSEWOOD trial, showcasing higher overall response rates. BRUKINSA is the first and only BTK inhibitor to show efficacy in this type of malignancy, with a broad label covering five oncology indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
BeiGene, Ltd.

Nasdaq:BGNE

BGNE Rankings

BGNE Stock Data

17.32B
762.01M
0.03%
48.09%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GRAND CAYMAN

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.